In Vivo Site Specific CAR-T Engineering Service via EDV/AAV Dual-Vector System

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Current in vivo CAR-T development faces significant challenges including off-target integration risks, insufficient site-specificity, phenotypic exhaustion from ex vivo manipulation, and prolonged drug development cycles with high manufacturing costs. To address these hurdles, we offer our In vivo Site-Specific CAR-T Engineering via EDV/AAV Dual-Vector Systems, which combines envelope-derived vesicles with AAV vectors to enable precise, targeted CAR integration at desired genomic loci directly within the body. This dual-vector platform ensures stable and durable CAR-T cell formation while minimizing genotoxicity and immunogenicity.

Introduction

Recent progress in T cell engineering has positioned chimeric antigen receptor (CAR) therapies as potent cancer treatments; however, their wider use is limited by cumbersome ex vivo production and safety risks linked to random vector integration. We present an in vivo strategy that achieves site-specific CAR insertion into the native TRAC locus using a dual-vector system: enveloped delivery vehicles for transient nuclease expression and adeno-associated viruses for homology-directed repair templates. Through a T cell-optimized AAV capsid and a targeted EDV, we enable precise, T cell-restricted transgene integration, eliminating ex vivo handling, off-target edits, and constitutive CAR signaling.

Fig.1 Precision in vivo engineering of CAR-T cells via combined EDV and AAV vectors. (OA Literature) Fig.1 Targeted in vivo CAR-T cell generation using a dual EDV-AAV delivery platform.¹

In Vivo Site Specific CAR-T Engineering via EDV/AAV Dual-Vector Systems at Creative Biolabs

Creative Biolabs delivers a complete, start-to-finish platform for producing locus-specific CAR-T cells directly inside the body. Our exclusive dual-vector technology supports accurate integration of sizable CAR sequences into chosen genomic sites. This approach removes the metabolic burden associated with conventional ex vivo culture and guarantees that each modified cell preserves a stem-like, minimally differentiated state, thereby enhancing long-term antitumor activity and persistence.

What We Can Offer

We offer an in vivo dual-vector platform combining EDV-mediated T cell delivery and AAV-driven TRAC-specific integration, enabling precise, off-the-shelf CAR-T engineering for both hematological and solid tumors.

Featured services of in vivo site-specific CAR-T engineering via EDV/AAV dual-vector systems at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

The target antigen sequence (e.g., scFv sequence).
Desired genomic integration site.
Specific T cell subset preferences.

Key Steps:

Workflow of in vivo site-specific CAR-T engineering via EDV/AAV dual-vector systems at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: A complete study deliverable compiling lentiviral titer measurements, genomic insertion mapping, and cytometric profiles of CAR surface expression.

Key Advantages

Targeted Delivery to Endogenous T Cells: EDV vectors engineered with T-cell-recognizing surface ligands enable selective intracellular delivery of gene-editing components specifically to T cells after systemic administration.
Safe Genomic Integration at a Defined Site: AAV donor vectors containing CAR cassettes with TRAC-locus homology arms facilitate precise knock-in at the native TRAC genomic safe harbor, minimizing risks of random integration and oncogenic transformation.
Physiologically Regulated CAR Expression to Reduce T-Cell Exhaustion: Driving CAR expression from the endogenous TRAC promoter ensures activation-dependent, natural expression levels, avoiding tonic signaling and supporting a stem-like memory phenotype for durable antitumor function.

FAQ

Q1: What is the risk of off-target integration?

A1: Our platform employs high-fidelity nuclease variants along with T-cell-restricted regulatory elements to confine gene insertion to the intended genomic safe harbor. Unlike standard lentiviral systems, which carry a risk of semi-random integration, this targeted approach substantially reduces unintended genomic alterations while preserving on-target efficiency.

Q2: Is lymphodepletion required for this in vivo approach?

A2: Unlike conventional CAR-T cell therapy, which typically relies on intensive conditioning regimens to create space for infused cells, our in vivo engineering strategy leverages the host's physiological T cell niche. This design often minimizes or entirely eliminates the need for aggressive lymphodepletion, thereby lowering treatment-related toxicities and simplifying the overall protocol.

Why Choose Us?

Creative Biolabs leads the ongoing transformation in in vivo cell engineering. Our CellRapeutics™ platform directly overcomes the shortcomings associated with random viral integration. Through the strategic pairing of tropism-enhanced AAV vectors with selective EDV delivery vehicles, our system enables highly efficient, locus-specific genomic insertion.

Customer Reviews

"The dual-vector system substantially advanced our work on intratumoral T-cell infiltration. Observed in vivo stemness levels surpassed those achieved through conventional ex vivo expansion." Dr. Al***rt S.

"In our B-cell malignancy model, the EDV/AAV platform delivered highly precise TRAC-targeted integration. This resolved the tonic signaling issues previously encountered with random lentiviral approaches." 2024, Sarah L***nz.

"By adopting direct in vivo engineering, we eliminated four months of process development. The resulting data met all regulatory requirements for clinical study authorization." Prof. Mi***el K.

How to contact us?

Creative Biolabs offers an advanced in vivo platform for site-specific CAR-T engineering, converting complex cell therapy into a programmable, single-administration biologic. Our dual EDV/AAV vector system enables precise TRAC-targeted integration, maintains T cell stemness, and accelerates the pathway toward clinical application.

For customized project planning or to request a tailored proposal, please reach out to our scientific support team.

Reference

Nyberg, William A et al. "In vivo site-specific engineering to reprogram T cells." Nature vol. 652,8110 (2026): 712-721. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1038/s41586-026-10235-x

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.